65,437 trials
Alcohol-Impaired Driving
Primary: Change in Number of Times Driving After Using Substances — 22.43; 26.50; 26.00 Driving Events
Peripheral Artery Disease
Primary: Time to Dementia Onset — 28.1; 32.6; 37.9; 44.8 Incidence rate per 1000 person year
Asthma
Primary: Time to Dementia Onset — 9.1; 5.6; 14.5; 14.2 Incidence rate per 1000 person year
Astigmatism · Presbyopia
Primary: Subjective Distance Vision — 77.1; 80.0 units on a scale
COVID
Primary: Efficacy - PaO2/FiO2 Ratio — 227; 209; 155; 248 mmHg (rounded)
Dementia
Primary: Phase 1: The Most Common Topics Related to Dementia Patient Care Skills — 15; 12; 18; 18 Participants
Melanoma · Head and Neck Cancer · Non Small Cell Lung Cancer
Primary: Number of Participants With Dose-limiting Toxicities (DLT) After Administration of Enoblituzumab and Pembrolizumab or Retifanlimab — 1; 0; 0; 0 Participants
Mild to Moderate Alzheimer's Disease
Primary: Number of Study Participants With at Least One Mild, Moderate, or Severe Treatment Emergent Adverse Events (TEAEs) — 36; 42; 39; 19 Participants
Peripheral Arterial Disease
Primary: Occurrence Rate of Radial Access Site Complications (Primary Safety Outcome) — 0 Participants
Mycosis Fungoides · Sezary Syndrome · Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8
Primary: Proportion of Overall Cutaneous Responders at Their 9th or Final Cycle (Cutaneous Complete Response [CR], Cutaneous 90 Response [CR90] or Cutaneous Partial Response…
Acute Heart Failure · Diuretics Drug Reactions
Primary: Mortality, Days in Hospital & Decongestion — 54.68; 44.16 % wins — p=0.357
Ischemic Stroke · Acute Stroke
Primary: ITT Cohort: Rate of Core Lab-adjudicated Reperfusion Success — 216 Participants — p=<0.0001
Olfactory Neuroblastoma · Esthesioneuroblastoma · Neoplasm of the Nasal Cavity
Primary: Percentage of Participants With an Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 — 0; 0; 37.5; 62.5 Percentage of…
Diabetes Type 2 · Diabetes Mellitus · Glucose Metabolism Disorders
Primary: Mean Change From Baseline in HbA1c (Tirzepatide 10 or 15 Milligram [mg]) — -26.1; -25.9; -9.96 millimoles per mole (mmol/mol) — p=<0.001
RESPIRATORY SYNCYTIAL VIRUS (RSV)
Primary: SSA: Percentage of Participants With Local Reactions Within 7 Days After Vaccination — 29.7; 10.2; 5.5; 0.4 Percentage of Participants